新辅助治疗在食管癌治疗中的应用

摘要/Abstract

摘要：

新辅助治疗联合手术是一种非常具有医学前景的食管癌临床治疗策略,综合其有效性和安全性,新辅助放疗可作为重度食管癌、不可切除食管癌的治疗手段,新辅助化疗在腺癌中治疗价值更高,新辅助放化疗可作为鳞状细胞癌患者的推荐治疗方案。

卜茜, 黄俊星. 新辅助治疗在食管癌治疗中的应用[J]. 国际肿瘤学杂志, 2020, 47(4): 244-248.

Bu Qian, Huang Junxing. Application of neoadjuvant therapy in the treatment of esophageal cancer[J]. Journal of International Oncology, 2020, 47(4): 244-248.

参考文献27

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. doi:10.3322/caac.v68.6
[2]	Chen W, Zheng R, Baade PD , et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016,66(2):115-132. DOI: 10.3322/caac.21338.
[3]	汪楣, 谷铣之, 黄国俊 , 等. 食管癌术前放射治疗的前瞻性临床研究[J]. 中华放射肿瘤学杂志, 2001,10(3):168-171. DOI: 10.3760/j.issn:1004-4221.2001.03.007.
[4]	Thumallapally N, Meshref A, Mousa M , et al. Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis[J]. J Gastrointest Oncol, 2017,8(5):825-832. DOI: 10.21037/jgo.2017.06.19.
[5]	Chan KKW, Saluja R, Delos Santos K , et al. Neoadjuvant treatments for locally advanced, resectable esophageal cancer: a network meta-analysis[J]. Int J Cancer, 2018,143(2):430-437. DOI: 10.1002/ijc.31312.
[6]	谭黎杰, 汪灏, 唐汉 . 局部进展期食管癌新辅助治疗的现状与展望[J]. 中华消化外科杂志, 2017,16(5):450-453. DOI: 10.3760/cma.j.issn.1673-9752.2017.05.003.
[7]	闫海霞, 符国胜 . 术前放疗对食管癌患者影响的临床分析[J]. 当代医学, 2011,17(16):21-22. DOI: 10.3969/j.issn.1009-4393.2011.16.014.
[8]	Zhu Y, Liu M, Yun X , et al. Meta-analysis for the therapeutic effect of neoadjuvant therapy in resectable esophageal cancer[J]. Pathol Oncol Res, 2017,23(3):657-663. DOI: 10.1007/s12253-016-0164-4.
[9]	Hara H, Tahara M, Daiko H , et al. Phase Ⅱ feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma[J]. Cancer Sci, 2013,104(11):1455-1460. DOI: 10.1111/cas.12274.
[10]	Pasquali S, Yim G, Vohra RS , et al. Survival after neoadjuvant and adjuvant treatments compared to surgery alone for resectable esophageal carcinoma: a network meta-analysis[J]. Ann Surg, 2017,265(3):481-491. DOI: 10.1097/SLA.000000000000-1905.
[11]	Ma S, Yan T, Liu D , et al. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy is safe and feasible for treatment of esophageal squamous cell carcinoma[J]. Thoracic Cancer, 2018,9(2):310-315. DOI: 10.1111/1759-7714.12590.
[12]	Zheng Y, Li Y, Liu X , et al. Reevaluation of neoadjuvant chemotherapy for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials over the past 20 years[J]. Medicine (Baltimore), 2015,94(27):e1102. DOI: 10.1097/MD.0000000000001102.
[13]	Tanaka K, Miyata H, Sugimura K , et al. miR-27 is associated with chemoresistance in esophageal cancer through transformation of normal fibroblasts to cancer-associated fibroblasts[J]. Carcinogenesis, 2015,36(8):894-903. DOI: 10.1093/carcin/bgv067.
[14]	Yoshida N, Baba Y, Shigaki H , et al. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma[J]. Int J Clin Oncol, 2016,21(6):1071-1078. DOI: 10.1007/s10147-016-0994-9.
[15]	van Hagen P, Hulshof MC, van Lanschot JJ , et al. Preoperative chemoradiotherapy for esophageal or junctional cancer[J]. New Engl J Med, 2012,366(22):2074-2084. DOI: 10.1056/NEJMoa1112088.
[16]	Shapiro J, van Lanschot JJB, Hulshof MCCM , et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial[J]. Lancet Oncol, 2015,16(9):1090-1098. DOI: 10.1016/s1470-2045(15)00040-6.
[17]	Mantziari S, Gronnier C, Renaud F , et al. Survival benefit of neoadjuvant treatment in clinical T₃N₀M₀esophageal cancer: results from a retrospective multicenter European study[J]. Ann Surg, 2017,266(5):805-813. DOI: 10.1097/SLA.000000000000-2402.
[18]	Yang H, Liu H, Chen Y , et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase Ⅲ multicenter, randomized, open-label clinical trial[J]. J Clin Oncol, 2018,36(27):2097-2083. DOI: 10.1200/JCO.2018.79.1483.
[19]	刘施亮, 习勉, 杨雅迪 , 等. 局部晚期食管鳞癌新辅助放化疗联合手术治疗的临床疗效分析[J]. 中华放射肿瘤学杂志, 2015,24(3):232-236. DOI: 10.3760/cma.j.issn.1004-4221.2015.03.002. doi:10.3760/cma.j.issn.1004-4221.2015.03.002
[20]	Hamai Y, Hihara J, Taomoto J , et al. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer[J]. Dis Esophagus, 2015,28(4):358-364. DOI: 10.1111/dote.12207.
[21]	Ychou M, Boige V, Pignon JP , et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011,29(13):1715-1721. DOI: 10.1200/JCO.2010.33.0597.
[22]	Ronellenfitsch U, Schwarzbach M, Hofheinz R , et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer, 2013,49(15):3149-3158. DOI: 10.1016/j.ejca.2013.05.029. doi:10.1016/j.ejca.2013.05.029
[23]	Alderson D, Cunningham D, Nankivell M , et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2017,18(9):1249-1260. DOI: 10.1016/s1470-2045(17)30447-3.
[24]	Kumagai K, Rouvelas I, Tsai JA , et al. Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: a direct and adjusted indirect comparison meta-analysis[J]. Eur J Surg Oncol, 2015,41(3):282-294. DOI: 10.1016/j.ejso.2014.11.039.
[25]	Stahl M, Walz MK, Riera-Knorrenschild J , et al. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): long-term results of a controlled randomised trial[J]. Eur J Cancer, 2017,81:183-190. DOI: 10.1016/j.ejca.2017.04.027. doi:10.1016/j.ejca.2017.04.027
[26]	Deng HY, Wang WP, Wang YC , et al. Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer[J]. Eur J Cardiothorac Surg, 2017,51(3):421-431. DOI: 10.1093/ejcts/ezw315.
[27]	Bibby BA, Reynolds JV, Maher SG . MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma[J]. PLoS One, 2015,10(7):e0134180. DOI: 10.1371/journal.pone.0134180.

新辅助治疗在食管癌治疗中的应用

Application of neoadjuvant therapy in the treatment of esophageal cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献27

相关文章15

编辑推荐

Metrics

本文评价

[1]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[2]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[3]	张文馨, 夏泠, 彭晋, 周福祥.甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[4]	万芳, 杨钢, 李睿, 万启晶.食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[5]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安.新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[6]	邵建强, 王鹏, 白杰, 李会欣, 王遵义, 徐志宏.银杏叶提取物诱导乳腺癌MCF-7细胞线粒体自噬的机制研究[J]. 国际肿瘤学杂志, 2024, 51(2): 65-72.
[7]	中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会.中国食管癌放射治疗指南（2023年版）[J]. 国际肿瘤学杂志, 2024, 51(1): 1-20.
[8]	高新雨, 李振江, 孙洪福, 韩丹, 赵倩, 刘成新, 黄伟.基于MR加速器的MR引导放疗在食管癌患者中的临床应用[J]. 国际肿瘤学杂志, 2024, 51(1): 37-42.
[9]	潘书兰, 刘畅, 贺平.福瑞替尼对三阴性乳腺癌血管生成、肿瘤生长及IRE1-ASK1-JNK通路的影响[J]. 国际肿瘤学杂志, 2023, 50(8): 457-462.
[10]	徐凡, 王婧, 毛宁, 王世雄, 李金茂.戈沙妥珠单抗治疗晚期三阴性乳腺癌1例[J]. 国际肿瘤学杂志, 2023, 50(8): 508-510.
[11]	山东省医学会肺癌食管癌多学科联合委员会.山东省医学会食管癌多学科规范化诊疗指南（2023年版）[J]. 国际肿瘤学杂志, 2023, 50(7): 385-397.
[12]	崔腾璐, 孙鹏飞.鼻咽低级别乳头状腺癌综合治疗1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(6): 382-384.
[13]	李彬, 张桂芳, 周林静, 杨小冬, 何秋立, 贾思思, 黄普超, 梁嘉欣.三阴性乳腺癌中PIK3CA基因状态与临床特征及预后的关系[J]. 国际肿瘤学杂志, 2023, 50(5): 263-267.
[14]	徐放, 朱文钿.肝细胞癌合并微血管侵犯术后辅助治疗现状[J]. 国际肿瘤学杂志, 2023, 50(5): 304-309.
[15]	杨洪娟, 孙云川, 何新颖, 毕建强, 肖丽.子宫内膜中肾样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2023, 50(4): 255-256.